146 related articles for article (PubMed ID: 11518063)
1. Neurochemical studies with St. John's wort in vitro.
Simmen U; Higelin J; Berger-Büter K; Schaffner W; Lundstrom K
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S137-42. PubMed ID: 11518063
[TBL] [Abstract][Full Text] [Related]
2. In vitro binding studies with two hypericum perforatum extracts--hyperforin, hypericin and biapigenin--on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters.
Gobbi M; Moia M; Pirona L; Morizzoni P; Mennini T
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S45-8. PubMed ID: 11518075
[TBL] [Abstract][Full Text] [Related]
3. Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system.
Simmen U; Burkard W; Berger K; Schaffner W; Lundstrom K
J Recept Signal Transduct Res; 1999; 19(1-4):59-74. PubMed ID: 10071750
[TBL] [Abstract][Full Text] [Related]
4. Preserved pharmacological activity of hepatocytes-treated extracts of valerian and St. John's wort.
Simmen U; Saladin C; Kaufmann P; Poddar M; Wallimann C; Schaffner W
Planta Med; 2005 Jul; 71(7):592-8. PubMed ID: 16041642
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of St John's wort in depression : what is known?
Butterweck V
CNS Drugs; 2003; 17(8):539-62. PubMed ID: 12775192
[TBL] [Abstract][Full Text] [Related]
6. In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs.
Butterweck V; Nahrstedt A; Evans J; Hufeisen S; Rauser L; Savage J; Popadak B; Ernsberger P; Roth BL
Psychopharmacology (Berl); 2002 Jul; 162(2):193-202. PubMed ID: 12110997
[TBL] [Abstract][Full Text] [Related]
7. Antagonist effect of pseudohypericin at CRF1 receptors.
Simmen U; Bobirnac I; Ullmer C; Lübbert H; Berger Büter K; Schaffner W; Schoeffter P
Eur J Pharmacol; 2003 Jan; 458(3):251-6. PubMed ID: 12504780
[TBL] [Abstract][Full Text] [Related]
8. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex.
Gobbi M; Valle FD; Ciapparelli C; Diomede L; Morazzoni P; Verotta L; Caccia S; Cervo L; Mennini T
Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep; 360(3):262-9. PubMed ID: 10543427
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the synaptosomal uptake inhibition of serotonin by St John's wort products.
Schulte-Löbbert S; Holoubek G; Müller WE; Schubert-Zsilavecz M; Wurglics M
J Pharm Pharmacol; 2004 Jun; 56(6):813-8. PubMed ID: 15231048
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.
Obach RS
J Pharmacol Exp Ther; 2000 Jul; 294(1):88-95. PubMed ID: 10871299
[TBL] [Abstract][Full Text] [Related]
11. St. John's wort extracts and some of their constituents potently inhibit ultimate carcinogen formation from benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1.
Schwarz D; Kisselev P; Roots I
Cancer Res; 2003 Nov; 63(22):8062-8. PubMed ID: 14633740
[TBL] [Abstract][Full Text] [Related]
12. Effects of oral administration of extracts of Hypericum perforatum (St John's wort) on brain serotonin transporter, serotonin uptake and behaviour in mice.
Hirano K; Kato Y; Uchida S; Sugimoto Y; Yamada J; Umegaki K; Yamada S
J Pharm Pharmacol; 2004 Dec; 56(12):1589-95. PubMed ID: 15563766
[TBL] [Abstract][Full Text] [Related]
13. Aqueous ethanolic extract of St. John's wort (Hypericum perforatum L.) induces growth inhibition and apoptosis in human malignant cells in vitro.
Hostanska K; Reichling J; Bommer S; Weber M; Saller R
Pharmazie; 2002 May; 57(5):323-31. PubMed ID: 12061257
[TBL] [Abstract][Full Text] [Related]
14. Current St John's wort research from mode of action to clinical efficacy.
Müller WE
Pharmacol Res; 2003 Feb; 47(2):101-9. PubMed ID: 12543057
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of pancreatic lipase by the constituents in St. John's Wort: In vitro and in silico investigations.
Hou XD; Guan XQ; Cao YF; Weng ZM; Hu Q; Liu HB; Jia SN; Zang SZ; Zhou Q; Yang L; Ge GB; Hou J
Int J Biol Macromol; 2020 Feb; 145():620-633. PubMed ID: 31883893
[TBL] [Abstract][Full Text] [Related]
16. St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats.
Butterweck V; Winterhoff H; Herkenham M
Mol Psychiatry; 2001 Sep; 6(5):547-64. PubMed ID: 11526469
[TBL] [Abstract][Full Text] [Related]
17. Effects of Hypericum perforatum (St. John's wort) on passive avoidance in the rat: evaluation of potential neurochemical mechanisms underlying its antidepressant activity.
Misane I; Ogren SO
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S89-97. PubMed ID: 11518084
[TBL] [Abstract][Full Text] [Related]
18. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties.
Barnes J; Anderson LA; Phillipson JD
J Pharm Pharmacol; 2001 May; 53(5):583-600. PubMed ID: 11370698
[TBL] [Abstract][Full Text] [Related]
19. Researching the antidepressant actions of Hypericum perforatum (St. John's wort) in animals and man.
Franklin M; Cowen PJ
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S29-37. PubMed ID: 11518072
[TBL] [Abstract][Full Text] [Related]
20. Screen of receptor and uptake-site activity of hypericin component of St. John's wort reveals sigma receptor binding.
Raffa RB
Life Sci; 1998; 62(16):PL265-70. PubMed ID: 9585174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
